Taf + Emtricitabine + Rilpivirine Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: (TAF) – 25 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg
Reference Brands: Odefsey(US & EU)
Category: Anti Viral
Odefsey is a once-daily HIV-1 treatment combining TAF, Emtricitabine, and Rilpivirine. FDA and EMA approved, it offers improved kidney and bone safety compared to TDF-based regimens and must be taken with food.
Product Description:
Odefsey is a once-daily, fixed-dose combination tablet containing Tenofovir Alafenamide (TAF) 25 mg, Emtricitabine 200 mg, and Rilpivirine 25 mg, used for the treatment of HIV-1 infection in virologically suppressed patients or treatment-naïve individuals without resistance to its components. Approved by the FDA and EMA, Odefsey is a TAF-based alternative to older TDF regimens like Complera/Eviplera, offering improved renal and bone safety. It is indicated for adults and adolescents (≥12 years and ≥35 kg) and must be taken with a meal. Odefsey simplifies therapy by combining three potent agents into a single-tablet regimen.
Taf + Emtricitabine + Rilpivirine — third party manufacturing & bulk supply
Taf + Emtricitabine + Rilpivirine is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Taf + Emtricitabine + Rilpivirine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Taf + Emtricitabine + Rilpivirine →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Tenofovir alafenamide + emtricitabine + rilpivirine is used for the treatment of HIV-1 infection in adults who are virologically suppressed. It helps maintain viral suppression and supports long-term HIV management as a complete once-daily regimen.
It is made from the active ingredients tenofovir alafenamide (TAF), emtricitabine, and rilpivirine. TAF and emtricitabine are nucleoside reverse transcriptase inhibitors, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor.
The main trade name is Odefsey in the USA, EU, and UK.
Odefsey is manufactured by Gilead Sciences in collaboration with Janssen.
The generic name is tenofovir alafenamide + emtricitabine + rilpivirine.
The primary brand name is Odefsey.
It is manufactured by Gilead Sciences in the USA and EU, along with authorized global production partners.
Related Products
Brincidofovir
Strength:
100 mg, 10 mg/ml
Form: Tablets / Oral suspension
Reference Brands: Tembexa (USA/EU)
View Details
Lenacapavir
Strength:
300 mg, 463.5 mg/1.5 mL
Form: Tablet / Injection
Reference Brands: Yeztugo (USA), Sunlenca (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
